Persistency, medication prescribing patterns, and medical resource use associated with multiple sclerosis patients receiving oral disease-modifying therapies: a retrospective medical record review

BACKGROUND: In the US, the approved multiple sclerosis (MS) oral disease-modifying therapies (ODMTs) are fingolimod (FTY), teriflunomide (TFN), and dimethyl fumarate (DMF). FTY and TFN are recommended with once-daily doses with no up-titration, whereas DMF treatment is recommended twice-daily (BID)...

Descripción completa

Detalles Bibliográficos
Autores principales: Nazareth, Tara, Friedman, Howard S., Navaratnam, Prakash, Herriott, Denise A., Ko, John J., Barr, Peri, Sasane, Rahul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5041514/
https://www.ncbi.nlm.nih.gov/pubmed/27683214
http://dx.doi.org/10.1186/s12883-016-0698-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5041514/
https://www.ncbi.nlm.nih.gov/pubmed/27683214
http://dx.doi.org/10.1186/s12883-016-0698-9

Ejemplares similares